If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Obesity, Decision Resources is offering an exclusive analyst call entitled How Will Sibutramine’s Suspension in Europe Affect its Future in the United States and What Now Lies Ahead for the Obesity Drug Market? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Following the recent suspension by the European Medicines Agency (EMEA) of the weight-loss agent sibutramine (Abbott Laboratories’ Meridia/Reductil) Decision Resources has updated its forecast for the obesity drug market. The EMEA’s decision was based on data from the SCOUT clinical trial, which found that the risk of heart attack or stroke associated with sibutramine’s use far outweighs its benefits. Sibutramine’s suspension leaves only one prescription weight-loss agent on the European market—Roche’s Xenical, which is also marketed as GlaxoSmithKline’s Alli (a half-dose over-the-counter version of Xenical). Following the EMEA’s action, the U.S. Food and Drug Administration (FDA) will now require sibutramine’s warning label to include stronger language and the drug’s future availability in the U.S. market could be in jeopardy. This 15-minute analyst call, presented by Therapeutic Area Director Donny Wong, Ph.D., will answer the following questions:
Dr. Wong will conduct a live Q & A session after the presentation. Registration How Will Sibutramine’s Suspension in Europe Affect its Future in the United States and What Now Lies Ahead for the Obesity Drug Market? February 11, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||||
Donny Wong, Ph.D. is the therapeutic area director for cardiovascular and metabolic disorders at Decision Resources, where he has authored market research reports on type 2 diabetes, obesity, dyslipidemia, diabetic complications, and other indications. Dr. Wong has more than 12 years of experience in scientific research and has conducted laboratory research at Harvard University, the Massachusetts Institute of Technology and the U.S. Department of Agriculture. Dr. Wong attended MIT and Williams College and earned M.M.Sc. and Ph.D. degrees from Harvard University.